Chayapat Rachatan is currently a Project Associate at HITAP. She supports the HTA and health system research. Her research studies focus on COVID-19 policy research and decision support, effectiveness evaluation of COVID-19 vaccine chatbot, cost analysis of governance system in health sector, situational analysis of infectious disease modelling in

Abstract   Objectives: Since 1985, the international healthcare community has recommended the ideal rate of caesarean section (CS) to be 10%–15% at the national level. The literature has reported that overused CS without necessary medical indications can be harmful to both maternal and chil

Since 2013, HITAP has supported HTA development and capacity building in the Philippines. In 2019, the Philippines mandated the provision of universal health coverage to all Filipinos. To support the decision-making for this promising undertaking, the partners continue their collaboration through technical assisatance on national HTA guidelines, on

Six potential interventions for implementation in the Bangkok Metropolitan Area were identified based on available evidence on effectiveness, feasibility, and cost: (i) clean air rooms; (ii) dust-free bed nets; purifiers; (iii) masking; (iv) clean cooking; (v) green screens, and (vi) metropolita

ดร. ภญ.ปฤษฐพร กิ่งแก้ว เป็นนักวิจัยโครงการประเมินเทคโนโลยีและนโยบายด้านสุขภาพ (HITAP) ตั้งแต่ปี พ.ศ. 2550 จบการศึกษาระดับปริญญาตรี สาขาเภสัชศาสตร์ มหาวิทยาลัยศรีนครินทรวิโรฒ ในปีพ.ศ. 2550 หลักสูตรโครงการร่วมระหว่างมหาวิทยาลัยศรีนครินทรวิโรฒ และมหาวิทยาลัยนอตติงแฮม (the University of Nottingham) ประเทศสหราชอาณาจักร ภายหลังได้รับทุนสนับสนุนการศึกษาต่

Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand Pattara Leelahavarong1*, Yot Teerawattananon1, Pitsaphun Werayingyong1, Chutima Akaleephan2, Nakorn Premsri3, Chawetsan Namwat3, Wiwat Peerapatanapoki

Pitsaphun Werayingyong, BPharm, MSc1, Nittaya Phanuphak, MD2, Kulkunya Chokephaibulkit, MD3, Sripen Tantivess, BPharm, PhD1, Nareeluk Kullert, BSc4, Kakanang Tosanguan, BPharm1, Rukmanee Butchon, MSc1, Nipunporn Voramongkol, MD4, Sarawut Boonsuk, MD5, Songyot Pilasant, BSc1, Wantanee Kulpeng, BSc1,

Kittiphong Thiboonboon1 , Benjarin Santatiwongchai1 ,Varit Chantarastapornchit1 , Waranya Rattanavipapong1 , Yot Teerawattananon1 Abstract Background For more than three decades, the number and influence of economic evaluations of healthcare interventions have been increasing and gaining atte

Abstract BACKGROUND: Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. This reimbursement policy has not covered for other genotypes of hepatitis

Abstract BACKGROUND: Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. This reimbursement policy has not covered for other genotypes of hepatitis C v